Drug Profile
BMS 943539
Alternative Names: BMS-943539; BMS-943539-01-001Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Proteins
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Undefined in Australia (IV, Infusion)
- 01 Dec 2010 Preclinical trials in Undefined indication in Australia (IV)